Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin heavy chain 4 (MYH4) encodes a major protein component of the thick filament in skeletal muscle, especially fast glycolytic (type IIb) fibers, and is responsible for muscle contraction through ATP hydrolysis and actin binding. It is a member of the sarcomeric myosin family with distinctive isoform-specific biochemical and physiological properties[2][3][1]. MYH4 is primarily expressed in adult skeletal muscle and determines fiber-type specific characteristics, such as contractile speed and metabolic profile. Genetic polymorphisms within MYH4 can affect muscle fiber composition and livestock meat quality[1]. In humans, MYH4 is associated with muscle function and implicated in rare diseases like cataract (OMIM) or muscle degeneration but is not established as a classic therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin heavy chain 4 (MYH4).